CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer
暂无分享,去创建一个
R. Bast | Wei Zhang | A. Sood | Da Yang | D. Rosen | Jinsong Liu | D. Gershenson | Xiaoxiang Chen | Jianfei Huang | Jing Zhang | D. Chang | Xuan Wang | Wenjun Cheng | Lizhou Jia
[1] Sohrab P Shah,et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma , 2012, Modern Pathology.
[2] Tae-Joong Kim,et al. Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer , 2011, Journal of gynecologic oncology.
[3] I. Shih,et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. , 2011, Gynecologic oncology.
[4] I. Shih,et al. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.
[5] L. Woelber,et al. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer , 2011, Journal of Cancer Research and Clinical Oncology.
[6] J. Hendriks,et al. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. , 2010, Gynecologic oncology.
[7] Ie-Ming Shih,et al. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.
[8] T. M. Brown,et al. A review of the current evidence for maintenance therapy in ovarian cancer. , 2009, Gynecologic oncology.
[9] Sokbom Kang,et al. Nadir CA‐125 level is an independent prognostic factor in advanced epithelial ovarian cancer , 2009, Journal of surgical oncology.
[10] Maurie Markman,et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma , 2009, Cancer.
[11] H. Chung,et al. Significance of preoperative serum CA‐125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer , 2008, Acta obstetricia et gynecologica Scandinavica.
[12] J. Baselga,et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] E. Høgdall. Cancer antigen 125 and prognosis , 2008, Current opinion in obstetrics & gynecology.
[14] W. McCluggage,et al. My approach to and thoughts on the typing of ovarian carcinomas , 2007, Journal of Clinical Pathology.
[15] B. Gerber,et al. Prognostic value of Ca 125 levels during primary therapy. , 2007, Anticancer research.
[16] D. Alberts,et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Zahurak,et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Proietto,et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Morandi,et al. CA125 Nadir values as a prognostic factor in epithelial ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[21] R. Kryscio,et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆ , 2003 .
[22] R. Ozols. Recurrent ovarian cancer: evidence-based treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] G. Rustin,et al. Role of tumour markers in monitoring epithelial ovarian cancer , 2000, British Journal of Cancer.
[24] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[25] C. Houghton,et al. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. , 1994, Gynecologic oncology.
[26] Jl Lewis,et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer , 1989, American journal of obstetrics and gynecology.
[27] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[28] Tae-Joong Kim,et al. Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. , 2011, Gynecologic oncology.
[29] J. Baselga,et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] Alexia Iasonos,et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. , 2007, Gynecologic oncology.
[31] J. Peace,et al. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] R. Kryscio,et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. , 2003, Gynecologic oncology.
[33] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[34] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.